Daclatasvir Side Effects
Medically reviewed by Drugs.com. Last updated on Jun 18, 2023.
Applies to daclatasvir: oral tablet.
General
In clinical trials, this drug was used in combination with sofosbuvir (with or without ribavirin), with peginterferon alfa/ribavirin, with asunaprevir, or with asunaprevir/peginterferon alfa/ribavirin. Fatigue, headache, and nausea were reported most often when used with sofosbuvir. Headache, anemia, fatigue, and nausea were reported most often when used with sofosbuvir and ribavirin. Fatigue, headache, pruritus, insomnia, influenza-like illness, dry skin, nausea, decreased appetite, alopecia, rash, asthenia, irritability, myalgia, anemia, pyrexia, cough, dyspnea, neutropenia, diarrhea, and arthralgia were reported most often when used with peginterferon alfa/ribavirin; the most common side effects of at least grade 3 severity were neutropenia, anemia, thrombocytopenia, and lymphopenia. The side effects and laboratory abnormalities reported with this drug in combination with peginterferon alfa/ribavirin was similar to those reported with peginterferon alfa/ribavirin alone, including in patients with cirrhosis. Headache, fatigue, diarrhea, nasopharyngitis, and nausea were reported most often when used with asunaprevir. Fatigue, headache, pruritus, asthenia, influenza-like illness, insomnia, rash, anemia, cough, dry skin, diarrhea, nausea, alopecia, irritability, pyrexia, and myalgia were reported most often when used with asunaprevir/peginterferon alfa/ribavirin.
The manufacturer product information for coadministered hepatitis C virus (HCV) antiviral drugs should be consulted.[Ref]
Other
Very common (10% or more): Fatigue (up to 41.5%), asthenia (up to 24.1%), influenza-like illness (up to 22.4%), pyrexia (up to 16.1%)
Common (1% to 10%): Hot flush, pain, weight decreased[Ref]
Nervous system
Very common (10% or more): Headache (up to 31.2%)
Common (1% to 10%): Dizziness, migraine, somnolence[Ref]
Dermatologic
Very common (10% or more): Pruritus (up to 26.1%), rash (up to 20.6%), dry skin (up to 17.8%), alopecia (up to 16.1%)
Postmarketing reports: Erythema multiforme[Ref]
Erythema multiforme has been reported with this drug as part of an asunaprevir regimen.[Ref]
Psychiatric
Very common (10% or more): Insomnia (up to 22.4%), irritability (up to 16.1%)
Common (1% to 10%): Depression, anxiety[Ref]
Hematologic
Of the patients reporting anemia, 43% received ribavirin in addition to this drug and sofosbuvir. During the study, anemia was not reported in the ribavirin-free treatment groups.
In trials of this drug with sofosbuvir (with or without ribavirin), grade 3 decreased hemoglobin was reported in 2% of patients; all of these patients received this drug with sofosbuvir and ribavirin.[Ref]
Very common (10% or more): Anemia (up to 20%), neutropenia (up to 14.8%)
Common (1% to 10%): Thrombocytopenia, decreased hemoglobin
Frequency not reported: Eosinophilia[Ref]
Respiratory
Very common (10% or more): Cough (up to 18.3%), nasopharyngitis (up to 13.7%), dyspnea (up to 12.3%)
Common (1% to 10%): Exertional dyspnea, nasal congestion, upper respiratory tract infection[Ref]
Gastrointestinal
Elevated lipase (at least 3.1 times the upper limit of normal [3.1 x ULN]) was reported in up to 4% of patients using this drug with sofosbuvir (with or without ribavirin).[Ref]
Very common (10% or more): Diarrhea (up to 17.6%), nausea (up to 16.6%)
Common (1% to 10%): Upper abdominal pain, abdominal pain, constipation, flatulence, gastroesophageal reflux disease, dry mouth, vomiting, elevated lipase[Ref]
Musculoskeletal
Very common (10% or more): Myalgia (up to 15.3%), arthralgia (up to 10.1%)
Common (1% to 10%): Back pain[Ref]
Metabolic
Very common (10% or more): Decreased appetite (up to 11.8%)[Ref]
Cardiovascular
Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with a regimen containing sofosbuvir. Cases of severe bradycardia and heart block have been reported with this drug in combination with sofosbuvir and concomitant amiodarone and/or other drugs that lower heart rate.[Ref]
Postmarketing reports: Symptomatic bradycardia, heart block, cardiac arrhythmias[Ref]
Hepatic
Common (1% to 10%): Increased ALT, increased AST, increased total bilirubin
Postmarketing reports: Hepatitis B reactivation[Ref]
Increased ALT (at least 5.1 x ULN), AST (at least 5.1 x ULN), and total bilirubin (at least 2.6 x ULN) were reported in up to 4%, up to 3%, and up to 8% of patients, respectively.
Grade 3/4 increased total bilirubin was reported in 5% of patients; all of these patients were coinfected with HIV and using concomitant atazanavir, had Child-Pugh A, B, or C cirrhosis, or were post-liver transplant.[Ref]
Genitourinary
Common (1% to 10%): Urinary tract infection
Ocular
Common (1% to 10%): Dry eye[Ref]
Frequently asked questions
More about daclatasvir
- Check interactions
- Compare alternatives
- Reviews (10)
- Dosage information
- During pregnancy
- Drug class: NS5A inhibitors
- Breastfeeding
Patient resources
Other brands
Related treatment guides
References
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Cerner Multum, Inc. Australian Product Information.
3. Product Information. Daklinza (daclatasvir). Bristol-Myers Squibb. 2015.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.